Searchable abstracts of presentations at key conferences in endocrinology

ea0094p399 | Neuroendocrinology and Pituitary | SFEBES2023

Paltusotine maintains IGF-1, GH, and symptom control in patients with acromegaly switched from injected octreotide or lanreotide monotherapy: Topline results from PATHFNDR-1, a phase 3, randomized, double-blind, placebo-controlled, multicenter study

R. Gadelha Monica , Casagrande, MD, PhD Alessandra , J. Strasburger MD Christian , Bidlingmaier Martin , Snyder MD Peter , Guitelman MD Mirtha , Boguszewski MD Cesar , Buchfelder MD Michael , Shimon MD Ilan , Raverot MD Gerald , Toth MD Miklos , Mezosi MD Emese , Doknic MD Mirjana , Fan PhD Xiaolin , Clemmons MD David , Keeley PhD Michael , J. Trainer MD Peter , Struthers PhD R. Scott , Krasner MD Alan , M.K. Biller MD Beverly

Paltusotine is a once-daily, oral, selectively-targeted SST2 agonist in development for the treatment of acromegaly. PATHFNDR-1 (NCT04837040) enrolled patients with acromegaly who had an IGF-1 ≤1xULN on a stable (>12 weeks) dose of lanreotide or octreotide. Patients were randomized 1:1 to receive paltusotine 40 mg/day or placebo for 36 weeks. During the first 24 weeks, the paltusotine dose was titrated (range 20-60 mg) based on IGF-1 and tolerance. Dose changes were ...

ea0035s18.1 | Endocrine disease during pregnancy | ECE2014

Pituitary tumours during pregnancy

Mezosi Emese

The morphology and function of pituitary gland are significantly altered in pregnancy. Complex changes can be seen at the level of pituitary and target hormones, binding globulins and the effect of placental hormones are also should be taken into consideration; this makes the diagnosis of pituitary dysfunction more complicated than in the non-pregnant stage. The incidence of pituitary adenomas in child-bearing age is 0.93/100 000. All pituitary tumors carry an increased risk f...

ea0056mte7 | (1) | ECE2018

Difficult cases of differentiated thyroid cancer

Mezosi Emese

The incidence of differentiated thyroid cancer (DTC) has increased worldwide which is mainly attributed to the more common detection of early stage DTC. The prognosis of early stage disease is excellent and the present ATA guidelines suggest less radical treatment and follow-up in these cases. TNM staging, risk classification, indication of radioiodine (RAI) treatment, evaluation of therapeutic response and TSH target range have been recently changed. However, 7–10% of DT...

ea0013s68 | A successful research career | SFEBES2007

MD VS PhD

Munir Alia

We are all aware of the current anxieties over the future of Academic Medicine and Modernising Medical Careers. 10 years ago the BMA cohort of 1995 Medical graduates: Medical Academic Career Intentions was performed. 545 doctors graduating in 1995 were followed up for 10 years. The key findings included: those doctors working in research were doing so to improve future career prospects or as a means to secure a National Training Number (NTN). However being in the transition pe...

ea0063p294 | Pituitary and Neuroendocrinology 1 | ECE2019

Menstrual dysfunction (MD) with ACTH dependent Cushing syndrome

Irgasheva Oydin , Yusupovna Khalimova Zamira

MD are the most frequent complaint of women with Cushing Syndrome at the time of diagnosis.Objective: To study the frequency of occurrence of MD in patients with Syndrome Cushing and to characterize their clinical and hormonal parallels. We investigated 34 women (average age of 27 years, variation in age from 18 to 30 years) with a newly identified ACTHA. The patients were divided into 4 groups: (1) the normal cycle is 26–31 days; (2) oligomenorrhea...

ea0035p20 | Adrenal cortex | ECE2014

Measurement of serum total cortisol using HPLC coupled ESI–TOF mass spectrometry

Tarjanyi Zita , Montsko Gergely , Mezosi Emese , Kovacs Gabor L

Cortisol is a glucocorticoid hormone with low molecular weight (362 Da) synthesized from cholesterol in the adrenal gland. The release is regulated by the hypothalamic–pituitary-adrenal (HPA) axis. Approximately 95% of the circulating amount is bound to proteins (CBG and albumin), but only the remaining free fraction is biologically active. Serum cortisol level is routinely analysed in laboratory medicine, though the widespread immunoassays (RIA and ECLIA) have the disadv...

ea0041gp221 | Thyroid Cancer | ECE2016

Predictive value of SPECT/CT after radioiodine therapy in differentiated thyroid cancer

Szujo Szabina , Schmidt Erzsebet , Szabo Zsuzsanna , Szekeres Sarolta , Zambo Katalin , Mezosi Emese

Purpose: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of SPECT/CT after radioiodine treatment of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis.Methods: One hundred and eighty-one consecutive patients with DTC were investigated after their first radioiodine treatment. The risk for recurrence based on ATA 2009 cl...

ea0037ep733 | Pituitary: clinical | ECE2015

Evaluation of GH secretion after stroke

Nemes Orsolya , Tarjanyi Zita , Szapary Laszlo , Ruzsa Beata , Bodis Beata , Bajnok Laszlo , Mezosi Emese

Objective: According to recent studies, impaired secretion of GH is a frequent finding after ischaemic stroke. The aim of our study was to compare various available GH stimulation tests in post-stroke patients.Design: Seventeen patients were included in the study (12 males; mean age: 60.5 years; mean BMI, 27.7 kg/m2) with a mean 19.6 (±7.3) months after stroke. For screening, glucagon and small dose (0.15 μg/kg) GHRH-arginine (sdGHRH...

ea0032p1000 | Thyroid (non-cancer) | ECE2013

Genetic examination of the TSHR gene in patients with congenital hypothyroidism: systematic survey of a Hungarian cohort

Labadi Arpad , Gellen Balazs , Ruzsa Beata , Rideg Orsolya , Kovacs Gabor L , Mezosi Emese , Persani Luca

Loss-of-function mutations in the TSH receptor (TSHR) gene are one of the most common known causes of congenital hypothyroidism (CH). While heterozygous mutations result in nonautoimmune isolated hyperthyrotropinemia, homozygous and compound heterozygous mutations may cause overt CH of various severity depending on the localization and type of the mutations.In our study we performed the systematic genetic analysis of the TSHR gene of a cohort of 85 Hunga...

ea0032p1097 | Thyroid cancer | ECE2013

The role of radioiodine SPECT/CT in differentiated thyroid cancer

Mezosi Emese , Bajnok Laszlo , Rucz Karoly , Weninger Csaba , Schmidt Erzsebet , Szabo Zsuzsanna , Szekeres Sarolta , Zambo Katalin

Introduction: Beside remnant ablation and treatment of known metastases, radioiodine treatment of differentiated thyroid cancer is suitable for the discovery of unknown or suspected metastatic disease. In this study, the clinical utility of SPECT/CT, a hybrid imaging method was evaluated after radioiodine therapy.Patients and methods: Between July 2007 and March 2012, 260 investigations were performed at 188 patients. Male:female ratio was 47:141. Every ...